Heart failure risk in kidney disease and type 2 diabetes
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial looks at how likely heart failure is for people who have both chronic kidney disease and type 2 diabetes. It aims to better understand and predict risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic kidney disease with an eGFR between 30 and 90.
- You have persistent albuminuria (protein in urine) between 100 and 5000 mg/g.
- You have type 2 diabetes and are on a stable dose of ACE inhibitor or ARB medication.
- You do not have type 1 diabetes.
- You do not have severe liver disease (Child-Pugh C).
- You have not taken Finerenone (Kerendia) in the last 8 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how diabetes medicines (GLP-1 and SGLT2, alone or together) affect the heart in people with type 2 diabetes who are at higher cardiovascular risk and have heart failure with preserved pumping function. It may help find safer or more effective ways to reduce heart problems.
This study looks at how cells talk to each other in people who have both diabetes and heart failure. It may help doctors understand these conditions better.
This study is looking at the link between kidney disease and heart disease. It aims to understand how heart problems affect people with chronic kidney disease. The trial does not test a new drug, but rather follows patients to learn more about their health.
This study tests a personalized medication approach to lower kidney and heart risks in people with type 2 diabetes and early-to-moderate kidney disease. It may help you if you have a high chance of heart problems and can start new medications.
This study tests new treatments to protect the heart and kidneys in people with long-standing type 1 diabetes. It aims to prevent or slow down complications like heart failure and kidney damage.
This trial tests whether adding finerenone to your current diabetes medications can better protect your heart and kidneys. It is for people with type 2 diabetes who already take an SGLT2 inhibitor and an ACE inhibitor or ARB.
Hear when a new CKD - Chronic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.